To Study Hepatotoxicity of Anti-TB Drugs Under Present Treatment Criteria

Abstract

First-line anti-tubercular medications, including isoniazid, rifampicin, pyrazinamide, and ethambutol, are necessary for the long-term treatment of tuberculosis (TB), a serious infectious disease. Hepatotoxicity is one of the most dangerous side effects of these medications, despite their great efficacy in treating tuberculosis. Treatment stoppage, low patient compliance, and decreased therapeutic success are all possible outcomes of drug-induced liver damage during tuberculosis treatment. This study examines the incidence, clinical manifestations, potential processes, risk factors, and therapeutic options of hepatotoxicity induced by anti-TB medications under current treatment guidelines. The risk of hepatotoxicity may be increased by a number of conditions, including old age, starvation, HIV infection, pre-existing liver disease, and genetic vulnerability. In order to enhance overall tuberculosis treatment outcomes, early diagnosis, appropriate monitoring, prompt action, and the development of safer treatment regimens all depend on an awareness of the hepatotoxic potential of anti-tubercular medications.